This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weber, W. Articles by Senekowitsch-Schmidtke, R. Search for Related Content PubMed PubMed Citation Articles by Weber, W. Articles by Senekowitsch-Schmidtke, R.

Therapeutic Effect of m-[¹³¹I]- and m-[¹²⁵I]Iodobenzylguanidine on Neuroblastoma Multicellular Tumor Spheroids of Different Sizes

Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar, Ismaningerstraße 22, 81675 Munich, Germany

m-[¹²⁵I]iodobenzylguanidine (m-[¹²⁵I]MIBG) has been suggested as an alternative to m-[¹³¹I]MIBG for the treatment of metastatic neuroblastoma to achieve a higher radiation dose in micrometastases. To compare these two radiopharmaceuticals, a mathematical model was developed in the present study that allows for the calculation of radiation dose rates within small spherical tumors for different distributions of ¹³¹I and ¹²⁵I. Furthermore, the relationship between tumor size and the therapeutic effects of m-[¹³¹I]- and m-[¹²⁵I]MIBG was studied in vitro using multicellular tumor spheroids of the neuroblastoma cell line SK-N-SH.

According to the calculations, higher mean dose rates can be achieved by m-[¹²⁵I]MIBG than by m-[¹³¹I]MIBG up to a tumor diameter of 100 µm when both substances are homogeneously distributed within the tumor. In larger tumors, however, mean dose rates achieved by ¹³¹I are up to 8-fold higher. Evaluation of various activity distributions demonstrated that even in tumors of less than 100 µm in diameter, marked heterogeneities of the dose rate can occur when m-[¹²⁵I]MIBG is not distributed homogeneously. By treatment with m-[¹³¹I]MIBG, the growth of tumor spheroids ranging from 100 to 250 µm in diameter was inhibited more effectively in the larger than in the smaller spheroids. The growth inhibition of spheroids treated with m-[¹²⁵I]MIBG was independent of the spheroid size. In consistency with the calculations, the therapeutic effect of m-[¹²⁵I]- and m-[¹³¹I]MIBG was equal in spheroids with diameters of about 100 µm. In larger spheroids, m-[¹³¹I]MIBG induced a more pronounced delay in spheroid growth than m-[¹²⁵I]MIBG. According to these calculations and in vitro data, m-[¹²⁵I]MIBG as a single agent does not seem to be a promising alternative to m-[¹³¹I]MIBG for treatment of metastatic neuroblastoma. However, the combined use of m-[¹³¹I]- and m-[¹²⁵I]MIBG may be more effective than treatment with m-[¹³¹I]MIBG alone.

¹ To whom requests for reprints should be addressed. Phone: 49-89-4140-2970; Fax: 49-89-4140-4950.

Received 5/22/96. Accepted 10/ 3/96.

This article has been cited by other articles:

				D. Emfietzoglou, K. Kostarelos, A. Papakostas, W.-H. Yang, A. Ballangrud, H. Song, and G. Sgouros Liposome-Mediated Radiotherapeutics Within Avascular Tumor Spheroids: Comparative Dosimetry Study for Various Radionuclides, Liposome Systems, and a Targeting Antibody J. Nucl. Med., January 1, 2005; 46(1): 89 - 97. [Abstract] [Full Text] [PDF]

				B. H. Kushner, S. Wolden, M. P. LaQuaglia, K. Kramer, D. Verbel, G. Heller, and N.-K. V. Cheung Hyperfractionated Low-Dose Radiotherapy for High-Risk Neuroblastoma After Intensive Chemotherapy and Surgery J. Clin. Oncol., June 1, 2001; 19(11): 2821 - 2828. [Abstract] [Full Text] [PDF]